Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers
Latest Information Update: 06 Feb 2025
Price :
$35 *
At a glance
- Drugs Selpercatinib (Primary)
- Indications Carcinoma; Squamous cell cancer; Thyroid cancer
- Focus Therapeutic Use
- 04 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 19 Aug 2024 Planned End Date changed from 10 Sep 2024 to 30 Nov 2025.
- 19 Aug 2024 Planned primary completion date changed from 10 Sep 2024 to 30 Nov 2025.